Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Penny R. Fleck"'
Publikováno v:
Diabetes Therapy
Introduction Adverse events and complications limit the long-term use of current antidiabetic treatment options for patients with type 2 diabetes mellitus (T2DM), particularly for older adults who are often receiving therapy for other comorbid condit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f412a5a8a54ca2113bf5e862c3a12e
https://doi.org/10.1007/s13300-014-0088-5
https://doi.org/10.1007/s13300-014-0088-5
Publikováno v:
Diabetes, Obesity and Metabolism. 15:906-914
Aim To prospectively evaluate the efficacy and safety of alogliptin versus glipizide in elderly patients with type 2 diabetes mellitus (T2DM) over 1 year of treatment. Methods This was a randomized, double-blind, active-controlled study of elderly T2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e6d508c6b83537693328c39e47cfa0b
https://doi.org/10.1111/dom.12102
https://doi.org/10.1111/dom.12102
This was a post hoc analysis of a 2-year, double-blind study of 2639 patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin monotherapy, which assessed achievement of a composite endpoint of sustained glycated haemoglobin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727329bf1b27221c67437310c4879a28
http://hdl.handle.net/11568/778959
http://hdl.handle.net/11568/778959
Autor:
Richard E. Pratley, Craig A. Wilson, Qais Mekki, Charles F. Burant, Penny R. Fleck, Ralph A. DeFronzo
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 97:1615-1622
Optimal management of type 2 diabetes remains an elusive goal. Combination therapy addressing the core defects of impaired insulin secretion and insulin resistance shows promise in maintaining glycemic control.The aim of the study was to assess the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::738d00623ddc5175a3e8c99b1a07c32e
https://doi.org/10.1210/jc.2011-2243
https://doi.org/10.1210/jc.2011-2243
Publikováno v:
Diabetes, Obesity and Metabolism. 13:1088-1096
Aim: To assess the efficacy and safety of adding alogliptin versus uptitrating pioglitazone in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone. Methods: In this randomized, double-blind, active-controlled,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cf0043fb6cf9acf3e309d04a6bf8106
https://doi.org/10.1111/j.1463-1326.2011.01463.x
https://doi.org/10.1111/j.1463-1326.2011.01463.x
Publikováno v:
Journal of the American Geriatrics Society. 57:2011-2019
OBJECTIVES: To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, in elderly (≥65) and younger (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea2fd003f1850d9bf5add9f99f1c4952
https://doi.org/10.1111/j.1532-5415.2009.02484.x
https://doi.org/10.1111/j.1532-5415.2009.02484.x
Autor:
Elisabeth R. Wann, Paul Covington, Penny R. Fleck, Qais Mekki, Michael Davenport, Aziz Karim, Christopher Ronald J
Publikováno v:
Clinical Therapeutics. 30:513-527
Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes.This study was conducted to characterize the pharmacokinetics, pharmacodynamics, and tolerability of single oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f20ea5f5ebaae05595a21ebfdd5242ef
https://doi.org/10.1016/j.clinthera.2008.03.005
https://doi.org/10.1016/j.clinthera.2008.03.005
Autor:
William B. White, Craig A. Wilson, Faiez Zannad, Cyrus R. Mehta, Hung Lam, Stuart Kupfer, William C. Cushman, Alfonso Perez, Penny R. Fleck, Christopher P. Cannon, Venu Menon, George L. Bakris
Publikováno v:
The Lancet
The Lancet, Elsevier, 2015, 385 (9982), pp.2067-2076. ⟨10.1016/S0140-6736(14)62225-X⟩
The Lancet, Elsevier, 2015, 385 (9982), pp.2067-2076. ⟨10.1016/S0140-6736(14)62225-X⟩
Summary Background The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in patients with type 2 diabetes and recent acute coronary syndromes. Concerns about excessive rates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a38138ae345c420f8bdaef074138813d
https://hal.univ-lorraine.fr/hal-01745763
https://hal.univ-lorraine.fr/hal-01745763
Autor:
David A. Morrow, Craig A. Wilson, Richard M. Bergenstal, Hung Lam, Stuart Kupfer, Penny R. Fleck, Alfonso Perez, Cyrus R. Mehta, William C. Cushman, F. Zannad, Simon Heller, Christopher P. Cannon, William B. White, George L. Bakris, Steven E. Nissen
Publikováno v:
Circulation. 130
BACKGROUND: Thorough evaluation of the cardiovascular (CV) safety of new drugs for diabetes mellitus (DM) is now mandated by the US FDA. Alogliptin, a dipeptidyl-peptidase 4 inhibitor, is one of a new drug class for treatment of DM. CV biomarkers may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5697f575ca42b868dbeace03bb95938
https://doi.org/10.1161/circ.130.suppl_2.17295
https://doi.org/10.1161/circ.130.suppl_2.17295
Publikováno v:
Diabetes, obesitymetabolism. 16(12)
Aims To evaluate the long-term durability of the efficacy of alogliptin compared with glipizide in combination with metformin in people with type 2 diabetes inadequately controlled on stable-dose metformin. Methods This multicentre, double-blind, act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0863169ed72f47aca58ffbafeb2b430
https://pubmed.ncbi.nlm.nih.gov/25132212
https://pubmed.ncbi.nlm.nih.gov/25132212